← Eichor
Study identifier: NCT06455514 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Post-CA Neuroprotection With Magnesium

Condition: Cardiac Arrest · Return of Spontaneous Circulation  ·  Sponsor: NYU Langone Health

PhasePhase 1
Planned participants178
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

The purpose of this pilot interventional study is to collect preliminary data on administering magnesium sulfate as a neuroprotective medication in patients who achieved Return of Spontaneous Circulation (ROSC) following Cardiac Arrest (CA). The primary aims are to assess the feasibility and safety of administering magnesium and measure serum markers of neuronal injury at prespecified time points in the post-cardiac arrest period. Because this is a pilot study with a limited sample size, the primary objective is to evaluate the precision and stability of the collected measures to inform the design and formal analysis in a larger trial.

This description comes directly from the study's public registry record.

Talk to the study team

Anelly Gonzales  ·  646-501-6923  ·  resuscitationlab@nyulangone.org

Natalia Leontovich  ·  646-501-6923  ·  resuscitationlab@nyulangone.org

Always discuss trial participation with your own doctor first.

Locations (1)

NYU Langone HealthNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06455514